VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates
Click Here to Manage Email Alerts
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David Kirn, MD, of 4D Molecular Therapeutics provides an update on two candidates for retinal diseases.
4D-150 demonstrated positive safety, retinal anatomy and durability results, as well as a reduction in the need for annualized anti-VEGF injections in patients with wet age-related macular degeneration, in the PRISM phase 2 clinical trial, he said.
The company has also filed an investigational new drug application for 4D-175 for the treatment of geographic atrophy.
“The next step in our development of these programs is to initiate phase 3 in Q1 of next year in wet AMD with 4D-150,” Kirn said. “We’ll also report out our first [diabetic macular edema] data in Q4 of this year in high-need DME patients.”
Collapse
Healio Interviews
Click Here to Manage Email Alerts